AEAndres F. Espinoza

Andres F. Espinoza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andres F. Espinoza has a total of 124 co-authors. Here are the top co-authors by number of shared publications:

  • Sanjeev A. Vasudevan

    Pediatric Surgical Oncology Laboratory, Divisions of Pediatric Surgery and Surgical Research, Michael E. DeBakey Department of Surgery, Texas Children’s Surgical Oncology Program, Texas Children’s Liver Tumor Program, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, USA

    6 shared publications
  • Alireza Shamshirsaz

    Fetal Care and Surgery Center, Division of Fetal Medicine and Surgery, Boston Children's Hospital Harvard Medical School Boston Massachusetts USA

    4 shared publications
  • Jimmy Espinoza

    Division of Fetal Intervention, Department of Obstetrics, Gynecology and Reproductive Sciences McGovern Medical School at UTHealth Houston Houston Texas USA

    4 shared publications
  • Richard S. Whitlock

    Baylor College of Medicine, Houston, TX

    4 shared publications
  • Andras Heczey

    Department of Pediatric Hematology and Oncology Texas Children's Hospital, Baylor College of Medicine Houston Texas USA

    3 shared publications
  • Kalyani R. Patel

    Department of Pathology and Immunology Texas Children's Hospital Baylor College of Medicine Houston Texas USA

    3 shared publications

Latest Publications

  • Open Access

    Teratoid Hepatoblastoma: Clinicopathologic Features and Outcomes

    by Brian T. Hickner, Andres F. Espinoza, Soo Jin Cho, Stephen Sarabia, Martin Urbicain, Ann Wang, Sanjeev A. Vasudevan, Dolores H. López‐Terrada, Kalyani R. Patel

    Background: Teratoid hepatoblastoma (HB) is a rare histologic subtype of the most common pediatric liver cancer. Understanding of the clinicopathologic features and outcomes of patients with this disease is currently limited.Methods: Multi‐institution, retrospective chart review was conducted to compare 20 children with teratoid HB to 129 children with non‐teratoid HB treated from 2004 to 2022.Results: Of the patients with teratoid HB, 31% showed teratoid histology in pre‐treatment biopsies. All 20 patients received neoadjuvant chemotherapy, with treated tumors showing melanin (14), neuroepithelium with or without glial cells (10), squamous epithelium and whorls (9), mucinous and/or non‐mucinous glandular elements (8), primitive endoderm/yolk sac‐like areas (3), and mature and/or immature ganglion cells (3). Metastatic and relapsed lesions did not show teratoid histology in this cohort. Teratoid HB was more frequent in males (M:F 1.9:1) and children <5 years old. Patients with teratoid HB were less chemoresponsive and had more metastases at presentation. Rates of prematurity, multifocal disease, vascular invasion, primary surgical management strategy (i.e., resection or transplant), relapse, and survival were comparable between the two groups.Conclusion: Teratoid HB occurs in younger patients and is more likely to be chemoresistant. Despite higher rates of metastases at presentation, survival was comparable between the two groups. This is one of the largest series evaluating the clinicopathologic features and outcomes of children with teratoid‐HB and is the first to directly compare outcomes between teratoid and non‐teratoid subtypes.


  • Open Access

    Incidence and Survival of Children and Adolescents With Wilms Tumor, United States, 2001–2020

    by Andres F. Espinoza, Ekene Onwuka, David A. Siegel, Shifan Dai, Sanjeev A. Vasudevan, Michael E. Scheurer, Philip J. Lupo

    Background: Wilms tumor (WT) is the most common pediatric malignancy of the kidney. Past studies describing WT incidence and survival used surveillance data with < 30% of the US population. We evaluated differences in WT incidence and survival comparing demographic groups and tumor characteristics.Methods: We analyzed new cases of WT among patients aged < 20 years at diagnosis by using incidence data from US Cancer Statistics (USCS) for 2003–2020 and 5‐year relative survival (RS) data from the National Program of Cancer Registries (NPCR) for 2001–2019. To assess incidence trends, average annual percent change (AAPC) was calculated by using joinpoint regression. Relative survival (RS) and all‐cause survival were calculated overall and by demographic and clinical variables.Results: During 2003–2020, 8218 cases of WT were reported in USCS, which represented an age‐adjusted incidence rate of 5.7 cases per million. Rates were the highest among females (6.3), children aged 0–4 years (17.2), and non‐Hispanic Black patients (7.1). Overall, trends remained stable (AAPC = −0.4, 95% CI: −1.4 to 0.4). Among 7567 cases of WT in NPCR, 5‐year RS was 92.6%. Patients with the lowest survival include the following: those aged 10–19 years (hazard ratio [HR] = 1.65, 95% CI: 1.02–2.65); non‐Hispanic Black patients (HR = 1.39, 95% CI: 1.11–1.76); those with regional stage (HR = 1.93, 95% CI: 1.47–2.54) or distant stage (HR = 5.12, 95% CI: 3.99–6.57); and patients from nonmetropolitan counties (HR = 1.46, 95% CI: 1.09–1.96). Individuals diagnosed during 2011–2019 (HR = 0.64, 95% CI: 0.53–0.77) had higher survival than those diagnosed during 2001–2010.Conclusions: The highest WT incidence rates were patients who were female, 0–4 years, and non‐Hispanic Black. Survival improved during the study period; survival differed by race, ethnicity, metropolitan status, and age. Further studies to delineate the causes of these disparities may improve outcomes.


  • Open Access

    Double-blind randomised trial of saline solution for gargling and nasal rinsing in SARS-CoV-2 infection

    by Sebastian R Espinoza, Lexton Trauffler, Amir Shamshirsaz, Alireza Shamshirsaz, Andres Espinoza, Jimmy Espinoza, Alice O'BRien

    While severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is no longer a global health emergency, it still affected around 765 000 000 people, resulting in over 7 000 000 deaths. The coronavirus enters into human cells targeting a specific receptor angiotensin converting enzyme-2, found in certain cells [1]. There is a close genetic similarity between severe acute respiratory syndrome […]


  • Open Access

    The impact of margins and re‐resection in pediatric synovial sarcoma

    by Andres F. Espinoza, Priya B. Shetty, Jillian C. Jacobson, Hannah Todd, Kelley Harrell, Alfred F. Trappey, John Doski, Eumenia C. Castro, Nicole I. Montgomery, M. Fatih Okcu, et al.

    Introduction: Synovial sarcoma is one of the most common soft tissue sarcomas in children. Guidelines regarding the adequate extent of resection margins and the role of re‐resection are lacking. We sought to evaluate the adequate resection margin and the role of re‐resection in predicting outcomes in children with synovial sarcomas.Methods: A cohort of 36 patients less than 18 years of age at diagnosis who were treated for localized synovial sarcoma at three tertiary pediatric hospitals between January 2004 and December 2020 were included in this study. Patient and tumor demographics, treatment information, and margin status after surgical resection were collected from the medical record. Clinical, treatment, and surgical characteristics, as well as outcomes including hazard ratios (HRs), event‐free survival (EFS), and overall survival (OS) were compared by resection margins group and re‐resection status.Results: Patients in the R1 resection group were significantly more likely to relapse or die compared to patients in the R0 resection group. However, there was no significant difference in EFS (HR 0.52, p = 0.54) or OS (HR 1.56, p = 0.719) in R0 patients with less than 5 mm margins compared to R0 patients with more than 5 mm margins. Patients with R1 on initial or re‐resection had significantly worse OS than patients who had R0 resection on initial or re‐resection (HR = 10.12, p = 0.005).Conclusion: This study re‐affirms that R0 resection is an independent prognostic predictor of better OS/EFS in pediatric synovial sarcoma. Second, our study extends this finding to report negative margins on initial resection or re‐resection is associated with better OS/EFS than positive margins on initial resection or re‐resection. Lastly, we found that there is no difference in outcomes associated with re‐resection or <5 mm margins for R0 patients, indicating that re‐resection and <5 mm margins are acceptable if microscopic disease is removed.


  • The impact of congenital heart disease on treatment and survival of patients with hepatoblastoma: A single‐center experience

    by Andres F. Espinoza, Ashley E. Montgomery, Nicholas C. Maamari, Heather A. Dickerson, Andras Heczey, Sanjeev A. Vasudevan, Jennifer H. Foster

    Background: Patients with hepatoblastoma (HB) have a higher risk of congenital heart defects (CHD). There is limited literature on the management and outcomes of these patients. The purpose of this study was to identify demographics and outcomes of these patients in a single tertiary referral center.Methods: An Institutional Review Board (IRB)‐approved retrospective chart review of patients with newly diagnosed HB from October 2004 to January 2021 was performed. CHD was defined as the presence of a septal defect, patent ductus arteriosus, pulmonary atresia, or bicuspid aortic valve. Chi‐square and t‐test were utilized for statistical analyses.Results: Of the 151 patients diagnosed with HB during the study timeframe, 29 patients were found to have CHD. Five‐year overall survival (OS) for non‐CHD HB patients was 81.9% compared to 68.9% in the CHD cohort (p = .12). The 5‐year OS for patients without surgically intervened CHD was 63.6% compared to 70.5% for those with surgically repaired CHD (p = .88). Pre‐treatment extent of tumor IV was present more often in patients with HB and CHD who passed away (6/9, 66.7%) compared to those who survived (3/16,18.8%, p = .01).Conclusions: Patients with HB and CHD have similar survival compared to those without CHD. Our data support that patients with HB and CHD should be treated with curative intent including cardiac surgical intervention, medical oncology therapy, and oncological surgery for their HB.


  • A subset of image‐defined risk factors predict completeness of resection in children with high‐risk neuroblastoma: An international multicenter study

    by Andres F. Espinoza, Rochelle Bagatell, Kieran McHugh, Arlene H. Naranjo, Collin Van Ryn, Yesenia Rojas, Karen Lyons, R. Paul Guillerman, Chaim Kirby, Penelope Brock, et al.

    Background: Image‐defined risk factors (IDRFs) were promulgated for predicting the feasibility and safety of complete primary tumor resection in children with neuroblastoma (NB). There is limited understanding of the impact of individual IDRFs on resectability of the primary tumor or patient outcomes. A multicenter database of patients with high‐risk NB was interrogated to answer this question.Design/methods: Patients with high‐risk NB (age <20 years) were eligible if cross‐sectional imaging was performed at least twice prior to resection. IDRFs and primary tumor measurements were recorded for each imaging study. Extent of resection was determined from operative reports.Results: There were 211 of 229 patients with IDRFs at diagnosis, and 171 patients with IDRFs present pre‐surgery. A ≥90% resection was significantly more likely in the absence of tumor invading or encasing the porta hepatis, hepatoduodenal ligament, superior mesenteric artery (SMA), renal pedicles, abdominal aorta/inferior vena cava (IVC), iliac vessels, and/or diaphragm at diagnosis or an overlapping subset of IDRFs (except diaphragm) at pre‐surgery. There were no significant differences in event‐free survival (EFS) and overall survival (OS) when patients were stratified by the presence versus absence of any IDRF either at diagnosis or pre‐surgery.Conclusion: Two distinct but overlapping subsets of IDRFs present either at diagnosis or after induction chemotherapy significantly influence the probability of a complete resection in children with high‐risk NB. The presence of IDRFs was not associated with significant differences in OS or EFS in this cohort.


  • A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma

    by Andres F. Espinoza, Roma H. Patel, Kalyani R. Patel, Andrew A. Badachhape, Richard Whitlock, Rohit K. Srivastava, Saiabhiroop R. Govindu, Ashley Duong, Abhishek Kona, Pavan Kureti, et al.


  • Open Access

    Navigating relapsed hepatoblastoma: Predictive factors and surgical treatment strategy

    by Andres F. Espinoza, Kalyani R. Patel, Priya B. Shetty, Richard S. Whitlock, Pavel Sumazin, Xinjian Yu, Stephen F. Sarabia, Martin Urbicain, Andras Heczey, Prakash Masand, et al.

    Objective: Hepatoblastoma (HB) is the most common primary hepatic malignancy in childhood. Relapse occurs in more than 50% of high‐risk patients with a high mortality due to ineffective salvage therapies. The purpose of this study is to identify risk factors for relapsed HB and predictors of survival in a single tertiary referral center.Methods: A retrospective chart review showed 129 surgically treated HB patients from October 2004 to July 2020. Of the cohort, 22 patients presented with relapsed HB. Relapse was defined as re‐appearance of malignancy after 4 weeks of normalized AFP and disappearance of all tumors on imaging.Results: Patients with relapsed HB had a 5‐year overall survival (OS) of 45.4% compared to 93.1% in those without relapse (p = 0.001). When comparing PRETEXT IV, microvascular invasion, metastatic disease, and age on multivariate logistic regression, only PRETEXT IV was an independent risk factor for relapsed HB with an OR of 2.39 (95% CI: 1.16–4.96; p = 0.019). Mixed epithelial and mesenchymal HB (12/19, 63.2%) was the most common histology of primary tumors while pure epithelial HB (13/15, 86.6%) was the most common relapsed histology. Combination of surgical and medical therapy for relapsed disease was predictive of survival with an HR of 16.3 (95% CI: 1.783–149.091; p = 0.013) compared to only chemotherapy.Conclusions: This study demonstrates that PRETEXT IV staging is an independent predictor of relapsed disease. The most common relapsed histology was epithelial, suggesting a potential selection or resistance of this component. Surgical resection is a critical component of multimodal therapy for relapsed HB.


  • Open Access

    DOUBLE BLIND RANDOMIZED CONTROLLED TRIAL OF SALINE SOLUTION GARGLING AND NASAL RINSING IN SARS-COV-2 INFECTION

    by S. Espinoza, L. Trauffler, A. Shamshirsaz, A. Espinoza, J. Espinoza, A. O'Brien

  • Surgical Management and Outcomes of Patients with Multifocal Hepatoblastoma

    by Richard S. Whitlock, Jorge I. Portuondo, Andres F. Espinoza, Rachel Ortega, N. Thao N. Galván, Daniel H. Leung, Dolores Lopez-Terrada, Prakash Masand, HaiThuy N. Nguyen, Kalyani A. Patel, et al.